NCT05737485View on ClinicalTrials.gov

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 18, 2023

Primary Completion Date

July 25, 2024

Study Completion Date

January 13, 2025

Conditions
Primary Ciliary Dyskinesia
Interventions
DRUG

RCT1100

RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer

Trial Locations (4)

2109

Macquarie University, Sydney

89113

PPD - Las Vegas Research Unit, Las Vegas

Unknown

New Zealand Clinical Research, Auckland

SW3 6NP

Royal Brompton Hospital, London

Sponsors
All Listed Sponsors
lead

ReCode Therapeutics

INDUSTRY

NCT05737485 - Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects | Biotech Hunter | Biotech Hunter